Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
Journal
American journal of clinical dermatology
ISSN: 1179-1888
Titre abrégé: Am J Clin Dermatol
Pays: New Zealand
ID NLM: 100895290
Informations de publication
Date de publication:
25 Aug 2023
25 Aug 2023
Historique:
accepted:
20
07
2023
medline:
25
8
2023
pubmed:
25
8
2023
entrez:
25
8
2023
Statut:
aheadofprint
Résumé
Abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, improved itch severity, sleep, and work productivity versus placebo in patients with moderate-to-severe atopic dermatitis. The aim of this study was to investigate relationships among itch, sleep, and work productivity in the phase III JADE MONO-2 clinical trial. A repeated-measures longitudinal model was used to examine relationships between itch (using the Peak Pruritus Numerical Rating Scale [PP-NRS] or Nighttime Itch Scale [NTIS]) and sleep disturbance/loss (using the Patient-Oriented Eczema Measure sleep item and SCORing AD Sleep Loss Visual Analog Scale) and, separately, between itch and work productivity (using the Work Productivity and Activity Impairment-Atopic Dermatitis Version 2.0 questionnaire). Mediation modelling was used to investigate the effect of treatment (abrocitinib vs placebo) on work impairment via improvements in itch and sleep. The relationships between itch/sleep and itch/work productivity were approximately linear. PP-NRS scores of 0, 4-6, and 10 were associated with 0 days, 3-4 days, and 7 days per week of disturbed sleep, respectively. PP-NRS or NTIS scores of 0-1, 4-5, and 10 were associated with 0-10%, 20-30%, and >50% overall work impairment, respectively. Seventy-five percent of the effect of abrocitinib on reducing work impairment was indirectly mediated by improvement in itch, followed by sleep. These results quantitatively demonstrate that reducing itch severity is associated with improvements in sleep and work productivity. Empirical evidence for the mechanism of action of abrocitinib showed that itch severity is improved, which reduces sleep loss/sleep disruption and, in turn, improves work productivity. NCT03575871. Atopic dermatitis (AD), also called atopic eczema, is a common skin disease that is associated with itch and reduced quality of life. Abrocitinib, a recently approved medicine for AD, was shown in clinical trials to improve itch, which is considered the most bothersome symptom to people with AD. Abrocitinib also improved sleep outcomes and work productivity in people with moderate or severe AD. It is unknown if improvement in itch can lead to improvement in sleep and work productivity. We analyzed data from the JADE MONO-2 study, which included 391 people who received treatment with abrocitinib or placebo for 12 weeks. We used mathematical modelling to study relationships between itch and sleep or work productivity. We also wanted to study if the improvements in itch and sleep with abrocitinib treatment had an impact on work productivity. We found that a relationship existed between itch, sleep disturbance, and work impairment; as itch improved, so too did sleep disturbance and work impairment. When people were treated with abrocitinib, they experienced relief from itch, which improved sleep, which in turn reduced work productivity loss. Larger and longer studies are needed to confirm these results. This analysis further informs the expectations of patients with moderate or severe AD as it relates to progression of symptom relief after treatment with abrocitinib.
Sections du résumé
BACKGROUND
BACKGROUND
Abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, improved itch severity, sleep, and work productivity versus placebo in patients with moderate-to-severe atopic dermatitis.
OBJECTIVE
OBJECTIVE
The aim of this study was to investigate relationships among itch, sleep, and work productivity in the phase III JADE MONO-2 clinical trial.
METHODS
METHODS
A repeated-measures longitudinal model was used to examine relationships between itch (using the Peak Pruritus Numerical Rating Scale [PP-NRS] or Nighttime Itch Scale [NTIS]) and sleep disturbance/loss (using the Patient-Oriented Eczema Measure sleep item and SCORing AD Sleep Loss Visual Analog Scale) and, separately, between itch and work productivity (using the Work Productivity and Activity Impairment-Atopic Dermatitis Version 2.0 questionnaire). Mediation modelling was used to investigate the effect of treatment (abrocitinib vs placebo) on work impairment via improvements in itch and sleep.
RESULTS
RESULTS
The relationships between itch/sleep and itch/work productivity were approximately linear. PP-NRS scores of 0, 4-6, and 10 were associated with 0 days, 3-4 days, and 7 days per week of disturbed sleep, respectively. PP-NRS or NTIS scores of 0-1, 4-5, and 10 were associated with 0-10%, 20-30%, and >50% overall work impairment, respectively. Seventy-five percent of the effect of abrocitinib on reducing work impairment was indirectly mediated by improvement in itch, followed by sleep.
CONCLUSION
CONCLUSIONS
These results quantitatively demonstrate that reducing itch severity is associated with improvements in sleep and work productivity. Empirical evidence for the mechanism of action of abrocitinib showed that itch severity is improved, which reduces sleep loss/sleep disruption and, in turn, improves work productivity.
CLINICAL TRIAL REGISTRATION
BACKGROUND
NCT03575871.
Atopic dermatitis (AD), also called atopic eczema, is a common skin disease that is associated with itch and reduced quality of life. Abrocitinib, a recently approved medicine for AD, was shown in clinical trials to improve itch, which is considered the most bothersome symptom to people with AD. Abrocitinib also improved sleep outcomes and work productivity in people with moderate or severe AD. It is unknown if improvement in itch can lead to improvement in sleep and work productivity. We analyzed data from the JADE MONO-2 study, which included 391 people who received treatment with abrocitinib or placebo for 12 weeks. We used mathematical modelling to study relationships between itch and sleep or work productivity. We also wanted to study if the improvements in itch and sleep with abrocitinib treatment had an impact on work productivity. We found that a relationship existed between itch, sleep disturbance, and work impairment; as itch improved, so too did sleep disturbance and work impairment. When people were treated with abrocitinib, they experienced relief from itch, which improved sleep, which in turn reduced work productivity loss. Larger and longer studies are needed to confirm these results. This analysis further informs the expectations of patients with moderate or severe AD as it relates to progression of symptom relief after treatment with abrocitinib.
Autres résumés
Type: plain-language-summary
(eng)
Atopic dermatitis (AD), also called atopic eczema, is a common skin disease that is associated with itch and reduced quality of life. Abrocitinib, a recently approved medicine for AD, was shown in clinical trials to improve itch, which is considered the most bothersome symptom to people with AD. Abrocitinib also improved sleep outcomes and work productivity in people with moderate or severe AD. It is unknown if improvement in itch can lead to improvement in sleep and work productivity. We analyzed data from the JADE MONO-2 study, which included 391 people who received treatment with abrocitinib or placebo for 12 weeks. We used mathematical modelling to study relationships between itch and sleep or work productivity. We also wanted to study if the improvements in itch and sleep with abrocitinib treatment had an impact on work productivity. We found that a relationship existed between itch, sleep disturbance, and work impairment; as itch improved, so too did sleep disturbance and work impairment. When people were treated with abrocitinib, they experienced relief from itch, which improved sleep, which in turn reduced work productivity loss. Larger and longer studies are needed to confirm these results. This analysis further informs the expectations of patients with moderate or severe AD as it relates to progression of symptom relief after treatment with abrocitinib.
Identifiants
pubmed: 37624488
doi: 10.1007/s40257-023-00810-7
pii: 10.1007/s40257-023-00810-7
doi:
Banques de données
ClinicalTrials.gov
['NCT03575871']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s).
Références
Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. J Allergy Clin Immunol. 2013;132(5):1132–8.
doi: 10.1016/j.jaci.2013.08.031
pubmed: 24094544
Williams H, Robertson C, Stewart A, Aït-Khaled N, Anabwani G, Anderson R, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol. 1999;103(1 Pt 1):125–38.
doi: 10.1016/S0091-6749(99)70536-1
pubmed: 9893196
Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic Dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583–90.
doi: 10.1016/j.jid.2018.08.028
pubmed: 30389491
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340–7.
doi: 10.1016/j.anai.2018.07.006
pubmed: 30025911
Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e2.
doi: 10.1016/j.anai.2017.10.039
pubmed: 29273118
Barbarot S, Auziere S, Gadkari A, Girolomoni G, Puig L, Simpson EL, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284–93.
doi: 10.1111/all.13401
pubmed: 29319189
Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(2):336–49.
doi: 10.1016/j.jaci.2016.06.010
pubmed: 27497276
de Bruin-Weller M, Gadkari A, Auziere S, Simpson EL, Puig L, Barbarot S, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026–36.
doi: 10.1111/jdv.16003
pubmed: 31587373
pmcid: 7318704
Ramirez FD, Chen S, Langan SM, Prather AA, McCulloch CE, Kidd SA, et al. Association of atopic dermatitis with sleep quality in children. JAMA Pediatr. 2019;173(5): e190025.
doi: 10.1001/jamapediatrics.2019.0025
pubmed: 30830151
pmcid: 6503516
Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Dermatol. 2015;135(1):56–66.
doi: 10.1038/jid.2014.325
pubmed: 25078665
Sack R, Hanifin J. Scratching below the surface of sleep and itch. Sleep Med Rev. 2010;14(6):349–50.
doi: 10.1016/j.smrv.2010.03.003
pubmed: 20494596
Fishbein AB, Vitaterna O, Haugh IM, Bavishi AA, Zee PC, Turek FW, et al. Nocturnal eczema: review of sleep and circadian rhythms in children with atopic dermatitis and future research directions. J Allergy Clin Immunol. 2015;136(5):1170–7.
doi: 10.1016/j.jaci.2015.08.028
pubmed: 26549635
Girolomoni G, Luger T, Nosbaum A, Gruben D, Romero W, Llamado LJ, et al. The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey. Dermatol Ther (Heidelb). 2020;11(1):117–30.
doi: 10.1007/s13555-020-00459-8
pubmed: 33180320
Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1645–51.
doi: 10.1080/03007995.2016.1195733
pubmed: 27240604
Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: an analysis using the National Health and Wellness Survey. J Am Acad Dermatol. 2017;77(2):274-9.e3.
doi: 10.1016/j.jaad.2017.04.019
pubmed: 28606711
Yano C, Saeki H, Ishiji T, Ishiuji Y, Sato J, Tofuku Y, et al. Impact of disease severity on work productivity and activity impairment in Japanese patients with atopic dermatitis. J Dermatol. 2013;40(9):736–9.
doi: 10.1111/1346-8138.12220
pubmed: 23834561
Legat FJ. Itch in atopic dermatitis—what is new? Front Med (Lausanne). 2021;8:644760.
doi: 10.3389/fmed.2021.644760
pubmed: 34026782
pmcid: 8137993
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345–60.
doi: 10.1016/S0140-6736(20)31286-1
pubmed: 32738956
Sutaria N, Adawi W, Goldberg R, Roh YS, Choi J, Kwatra SG. Itch: pathogenesis and treatment. J Am Acad Dermatol. 2022;86(1):17–34.
doi: 10.1016/j.jaad.2021.07.078
pubmed: 34648873
Kwatra SG, Misery L, Clibborn C, Steinhoff M. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clin Transl Immunol. 2022;11(5): e1390.
doi: 10.1002/cti2.1390
Misery L. Sleep disturbance and psoriasis. J Eur Acad Dermatol Venereol. 2022;36(5):633.
doi: 10.1111/jdv.18081
pubmed: 35416364
Cheng FL, An YF, Han ZQ, Li C, Li ZQ, Yang PC, et al. Period2 gene regulates diurnal changes of nasal symptoms in an allergic rhinitis mouse model. Int Forum Allergy Rhinol. 2020;10(11):1236–48.
doi: 10.1002/alr.22607
pubmed: 32613762
pmcid: 7689743
Chang YS, Chiang BL. Sleep disorders and atopic dermatitis: A 2-way street? J Allergy Clin Immunol. 2018;142(4):1033–40.
doi: 10.1016/j.jaci.2018.08.005
pubmed: 30144472
Cibinqo 100 mg film-coated tablets. Summary of product characteristics. Kent: Pfizer Limited; 2021. (09/10/2021).
Japan's MHLW approves Pfizer’s Cibinqo
European Medicines Agency. Cibinqo
Cibinqo (abrocitinib) tablets, for oral use. Prescribing information. New York: Pfizer Inc; 2023. (02/2023).
Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371–9.
doi: 10.1001/jamadermatol.2019.2855
pubmed: 31577341
pmcid: 6777226
Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–66.
doi: 10.1016/S0140-6736(20)30732-7
pubmed: 32711801
Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–73.
doi: 10.1001/jamadermatol.2020.1406
pubmed: 32492087
Bieber T, Simpson EL, Silverberg JI. Abrocitinib versus placebo and dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101–12.
doi: 10.1056/NEJMoa2019380
pubmed: 33761207
Eichenfield LF, Flohr C, Sidbury R. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: results from JADE TEEN. J Dermatol. 2021;157(10):1165–73.
Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104–12.
doi: 10.1016/j.jaad.2021.05.075
pubmed: 34416294
Thaci T, Bieber T, Simpson EL, Silverberg JI, Paul C, Sinclair R. A phase 3 study to investigate the efficacy and safety of abrocitinib and dupilumab in comparison with placebo in adults with moderate-to-severe atopic dermatitis. 29th EADV Congress. Virtual; 2020.
Yosipovitch G, Fonacier L, Ständer S, Su J, Gooderham M, Szepietowski J, et al. Pruritus, sleep, and productivity: a post hoc analysis of abrocitinib versus placebo in patients with moderate-to-severe atopic dermatitis (AD) from JADE MONO-2. J Allergy Clin Immunol. 2021;147(2, Supplement):AB34.
doi: 10.1016/j.jaci.2020.12.158
Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbe A, Nelson L, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–9.
doi: 10.1111/bjd.17744
pubmed: 30729499
pmcid: 6850643
Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. 2nd ed. Hoboken: Wiley; 2011.
doi: 10.1002/9781119513469
Bushmakin AG, Cappelleri JC. A practical approach to quantitative validation of patient-reported outcomes: a simulation-based guide using SAS. Hoboken: Wiley; 2022.
doi: 10.1002/9781119376354
Iacobucci D. Mediation analysis. Thousand Oaks: SAGE Publications, Inc.; 2008.
doi: 10.4135/9781412984966
Matterne U, Apfelbacher CJ, Loerbroks A, Schwarzer T, Buttner M, Ofenloch R, et al. Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. Acta Derm Venereol. 2011;91(6):674–9.
doi: 10.2340/00015555-1159
pubmed: 21879245
Carskadon MA, Acebo C, Jenni OG. Regulation of adolescent sleep: implications for behavior. Ann N Y Acad Sci. 2004;1021:276–91.
doi: 10.1196/annals.1308.032
pubmed: 15251897
Fuligni AJ, Chiang JJ, Tottenham N. Sleep disturbance and the long-term impact of early adversity. Neurosci Biobehav Rev. 2021;126:304–13.
doi: 10.1016/j.neubiorev.2021.03.021
pubmed: 33757816
Institute of Medicine Committee on Sleep Medicine and Research. The National Academies Collection: reports funded by National Institutes of Health. In: Colten HR, Altevogt BM, editors. Sleep disorders and sleep deprivation: an unmet public health problem. Washington: National Academies Press (US) National Academy of Sciences; 2006.
Lavery MJ, Stull C, Kinney MO, Yosipovitch G. Nocturnal pruritus: the battle for a peaceful night’s sleep. Int J Mol Sci. 2016;17(3):425.
doi: 10.3390/ijms17030425
pubmed: 27011178
pmcid: 4813276
Cappelleri JC, Zou KH, Bushmakin AG, Ma J, Alemayehu D, Symonds T. Patient-reported outcomes: measurement, implementation and interpretation. Chapman and Hall/CRC Press; 2013.
doi: 10.1201/b16139